Fundraisings and IPOs

Date: 2018-09-26

Type of information: Series B financing round

Company: Minoryx Therapeutics (Spain)

Investors: Chiesi Ventures (Italy) Caixa Capital Risc (Spain) HealthEquity (Spain) Fund+ (Belgium) Idinvest Partners (France) Kurma Partners (France) Sambrinvest (Belgium) Kurma Partners (France) Ysios Capital (Spain) SFPI-FPIM, S.R.I.W

Amount: €21.3 million

Funding type: series B financing round

Planned used:

  • The proceeds will enable Minoryx Therapeutics to expand the list of indications for its lead compound, MIN-102, as well as to conduct a new clinical trial for a second orphan central nervous system (CNS) indication.
  • MIN-102 is a novel, orally bioavailable and selective PPAR gamma agonist with a superior profile for central nervous system-related diseases. It is currently in a phase 2/3 clinical trial for the treatment of adrenomyeloneuropathy (AMN). The trial enrolls adult male patients affected by AMN, the most frequent phenotype of X-linked adrenoleukodystrophy (X-ALD), in Europe and the US, with results expected in 2020.


  • • On September 26, 2018, Minoryx Therapeutics announced the completion of a Series B funding round of €21.3M. The funding round was led by Fund+, joined by SFPI-FPIM, S.R.I.W. and Sambrinvest, in addition to all Series A investors (Ysios Capital, Kurma Partners, Roche Venture Fund, Idinvest Partners, Chiesi Ventures, Caixa Capital Risc and HealthEquity). Following this Series B funding round, two new members will join the Board of Directors of Minoryx: Philippe Monteyne and Gery Lefebvre, representing Fund+ and S.R.I.W., respectively.

Therapeutic area: Rare diseases

Is general: Yes